Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Adult Systemic Sclerosis (DAISY)
jRCT2051230127Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial in systemic sclerosis (SSc) and scleroderma comparing Anifrolumab arm with Placebo arm (2 arms). Primary endpoint: Composite Response based on Revised CRISS-25 at Week 52. Started Feb 2024; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)scleroderma
Beyond the preview
Go deeper on jRCT2051230127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230127.